Bolt Biotherapeutics
BOLT
61 hedge funds and large institutions have $514M invested in Bolt Biotherapeutics in 2021 Q2 according to their latest regulatory filings, with 15 funds opening new positions, 18 increasing their positions, 16 reducing their positions, and 24 closing their positions.
13% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 16
10% more capital inflows, than outflows
Capital inflows: $89.5M | Capital outflows: $81.5M
0.38% more ownership
Funds ownership: 91.24% → 91.61% (+0.38%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
13% less funds holding
Funds holding: 70 → 61 (-9)
38% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
+$14.6M |
| 2 |
Holocene Advisors
New York
|
+$11.7M |
| 3 |
Suvretta Capital Management
New York
|
+$10.8M |
| 4 |
Morgan Stanley
New York
|
+$5.51M |
| 5 |
Goldman Sachs
New York
|
+$4.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Avidity Partners Management
Dallas,
Texas
|
-$21.5M |
| 2 |
Deerfield Management
New York
|
-$11.5M |
| 3 |
Farallon Capital Management
San Francisco,
California
|
-$8.23M |
| 4 |
Sphera Funds Management
Tel Aviv,
Israel
|
-$7.93M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$5.95M |
BOLT Hedge Fund Activity: Q2 2021 in Review
61 of the 5,769 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q2 2021, worth a combined $514M — down 50% from $1.04B a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of BOLT and 15 opened new positions — a net loss of 9 holders — while 16 trimmed existing stakes and 18 added.
The largest buyer was Board of Trustees of The Leland Stanford Junior University, opening a new position worth an estimated $14.6M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $21.5M sold.
- 61 institutional investors held Bolt Biotherapeutics (BOLT) as of Q2 2021, down from 70 in Q1 2021.
- Funds reported $514M of Bolt Biotherapeutics stock for Q2 2021, down 50% quarter-over-quarter.
- 15 funds opened new Bolt Biotherapeutics positions in Q2 2021 and 24 closed out, a net change of -9 holders.
- The largest Bolt Biotherapeutics buyer in Q2 2021 was Board of Trustees of The Leland Stanford Junior University, an estimated $14.6M added.
- The largest Bolt Biotherapeutics seller in Q2 2021 was Avidity Partners Management, an estimated $21.5M sold.
Based on aggregated 13F filings for Q2 2021.